Core Viewpoint - Jingtai Holdings (02228) has seen a significant increase in stock price, rising over 4% today and nearly 50% for the month, driven by positive developments in its subsidiary ReviR's innovative drug pipeline RTX-117 [1] Group 1: Company Developments - Jingtai Technology announced that its incubated company ReviR has achieved a milestone with the successful dual approval of RTX-117 in both China and the U.S. [1] - ReviR will pay Jingtai a milestone payment totaling tens of millions of Hong Kong dollars as part of this achievement [1] - Jingtai has the right to participate in revenue sharing from the sales and subsequent licensing of the RTX-117 pipeline [1] Group 2: Market Analysis - Guolian Minsheng Securities published a report stating that Jingtai Holdings has established a competitive moat in the AI pharmaceutical sector through its software and hardware technology accumulation, platform-based business model, and strategic positioning [1] - The clinical approval of RTX-117 marks the beginning of the value realization phase for Jingtai's technology platform, with significant potential for performance elasticity and valuation reconfiguration as the collaboration pipeline continues to expand [1]
港股异动 | 晶泰控股(02228)再涨超4% ReviR创新药RTX-117获中美临床批件